LBT Innovations (ASX:LBT) share price plummets 14% despite positive update

The company's shares are off to a bad start this week…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The LBT Innovations Limited (ASX: LBT) share price is deep in the red today. This comes regardless of the medical technology company providing investors with a positive update yesterday.

At the time of writing, LBT Innovations shares are down a sizeable 14.29% to 12 cents apiece.

doctor looks out window resting head in hand

Image source: Getty Images

What did LBT Innovations announce?

According to its announcement, LBT Innovations advised Clever Culture Systems (CCS) has signed an exclusive distribution agreement with Thermo Fisher Scientific.

CCS is a joint-venture company owned equally by LBT Innovations and German medical equipment group Hettich.

Thermo Fisher is a leading provider of instrumentation and consumables in the US microbiology market.

The 5-year deal will see Thermo Fisher become the exclusive distributor for the company's automated culture plate reader, APAS Independence, in the US.

APAS Independence is the first and only FDA-cleared automated culture plate reader available in the United States. The innovative technology uses advanced imaging and artificial intelligence to interpret bacterial growth on culture plates.

Under the agreement, Thermo Fisher will engage in sales and marketing activities for APAS Independence in the US. In addition, the company will also provide installation, maintenance and support services to customers.

The agreement is a major milestone for LBT Innovations as it will provide sales and commercial activities in the US market which is the largest in the world. It offers more than 1,500 target laboratories for the potential placement of APAS Independence readers.

LBT Innovations CEO and managing director Brent Barnes commented:

This is a really important milestone for LBT and represents a major step forward in our commercialisation strategy in the United States.

We have spoken previously about the importance of appointing well recognised, leading distributors to support our sales efforts in key markets. Thermo Fisher is a leader in microbiology that is recognised globally, and we will benefit greatly from the depth and strength of their sales team in the United States…

We are very pleased to now have two of the world's largest microbiology companies selling our technology across the two main markets of the United States and Europe, which is a further validation of benefits of our technology.

LBT Innovations share price summary

Since the beginning of the year, LBT Innovations shares have moved in circles, remaining relatively unchanged for the period. When zooming out to the last 12 months, however, its shares are down around 8%.

LBT Innovations presides a market capitalisation of roughly $33 million and has over 289 million shares on its books.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 healthcare shares to buy amid sector rout

The experts are backing these stocks for price growth.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

Are investors taking a big gamble chasing 4DX shares higher and higher?

Investor interest in this ASX healthcare tech stock is booming.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »